Tokyo, May 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061478) titled 'Clinical Evaluation of Adherence to Migraine Preventive Medications' on May 19.
Study Type:
Observational
Primary Sponsor:
Institute - University of Tsukuba, Mito Medical Center
Condition:
Condition - migraine
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Migraine prevention includes both oral and injectable therapeutic options, with patients typically favoring oral medications. Conventional oral preventive agents have limited immediate efficacy and are often associated with adverse effects, leading to suboptimal adherence. Gepants represent a novel class of oral migraine preventives with demonstrated efficacy and a favorable safety profile, raising expectations for better adherence; nevertheless, empirical data on adherence remain unavailable.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Outpatients diagnosed with migraine by headache specialists according to the International Classification of Headache Disorders, 3rd edition, who are able to complete a headache diary, will be eligible. Participants must be initiating an oral preventive medication for migraine. There will be no restrictions on age or sex.
Key exclusion criteria - atients considered inappropriate for inclusion based on the clinical judgment of the attending physician.
Target Size - 60
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 04 Month 14 Day
Date of IRB - 2026 Year 04 Month 29 Day
Anticipated trial start date - 2026 Year 05 Month 07 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070331
Disclaimer: Curated by HT Syndication.
